A meta-analysis of 15 studies with more than 220,000 individuals showed that a mindset of optimism was associated with reduced risk of CV events and all-cause mortality.

ESC 2019 The THEMIS study evaluated the effect of ticagrelor vs. placebo on top of aspirin in diabetes patients with stable coronary artery disease. Netto clinical benefit depended on having a history of PCI or not.

In a large cohort study of 1.3 million participants, both systolic and diastolic hypertension were associated with composite of MI, ischemic stroke and hemorrhagic stroke, independent of thresholds defining hypertension.

In a meta-analysis of 21 RCTs including diverse populations, supplementation with vitamin D did not result in a reduction of MACE, MI, stroke/CVA, CV mortality and all-cause mortality compared to placebo.

ENGAGE AF-TIMI 48 data show that BMI was negatively associated with risk of stroke/SEE and positively associated with risk of bleeding, although sex differences were seen.

Dabigatran therapy did not result in a reduction of recurrent strokes compared to aspirin use after embolic stroke of undetermined source, whereas risk of nonmajor bleeding was higher with dabigatran.

A single-center prospective PCI-registry showed an independent association of high residual inflammatory risk and adverse clinical outcomes in patients undergoing PCI with LDL-c ≤70 mg/dL at baseline.

The exploratory ELIMINATE-AF study demonstrated that uninterrupted treatment with edoxaban represents an alternative to continuous VKA in patients undergoing catheter ablation of AF.

ESC HF 2019 A subanalysis of the COMMANDER-HF trial demonstrated that low dose rivaroxaban decreased stroke/TIA risk in patients with HFrEF, sinus rhythm and CAD without increase in major bleeding.

In individuals without CVD history in the ARIC study, increase in troponin I, measured by a high sensitivity assay, was associated with ASCVD, global CVD, CHD, stroke, HF hospitalization, and all-cause mortality.

In women, longer total exposure to antibiotics in middle- and late adulthood was significantly associated with risk of CVD in later life, and antibiotic use in middle adulthood with risk of CHD but not of stroke.

The FDA has approved alirocumab to reduce the risk of MI, stroke, and unstable angina requiring hospitalization in adults with established CVD, based on ODYSSEY OUTCOMES data.